APC-366 tryptase inhibitor data

ARRS and partner Bayer AG (Leverkusen, Germany) announced preliminary results from a Phase IIa study of a nebulized formulation of APC-366 in 16

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE